ClinicalTrials.gg
CompletedNCT00924703Updated Oct 12, 2021Results posted

Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

A Phase 2 interventional study of rAvPAL-PEG in Phenylketonuria, sponsored by BioMarin Pharmaceutical. Completed at 14 sites in United States. Open to participants aged 16 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-10-12.

Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
16 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.

Enrollment
3rd of 10
68 · median 39
Started
2010
the only one that year
Phase 2
4 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
10 of 10
BioMarin Pharmaceutical

Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 3rd largest by enrollment, is the only one that started in 2010, is one of 4 in phase 2, and was the 3rd registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegvaliase

pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 16 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pegvaliase in Phenylketonurias, or all of them as a file.
02

Study summary

This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.

Read the detailed description

PAL-003 is designed to evaluate long-term treatment of subjects who are continuing to take rAvPAL-PEG. Subjects'previous rAvPAL-PEG dosing will continue in PAL-003. In PAL-003, each subject's dose will be adjusted as needed to attain or maintain blood Phe concentrations of 60-600 µmol/L. rAvPAL-PEG dose will be based on either a subject's weight or will be a fixed dose (subjects who have maintained blood Phe levels to 60-600 µmol/L for at least 2 consecutive weeks and who have maintained a stable rAvPAL-PEG dose for at least 2 consecutive weeks). Doses will be evaluated on an individual basis.

03

Conditions studied

  • Phenylketonuria

Browse trials for

04

Who can participate

Ages eligible
16 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have completed participation in previous rAvPAL-PEG studies.
  • Willing and able to provide written, signed , or, in the case of participants under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures.
  • Willing and able to comply with all study procedures.
  • Females of must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
  • Sexually active subjects must be willing to use an acceptable method of while participating in the study.
  • Maintained a stable diet.
  • In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and (ECG) at Screening.

Exclusion criteria

Exclusion Criteria:

  • Use of any product (with the exception of rAvPAL-PEG) or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Use of any medication that is intended to treat PKU within 14 days prior to the administration of study drug.
  • Use or planned use of any injectable drugs containing PEG (other than rAvPAL-PEG), including Depo-Provera during study participation.
  • A prior reaction that included systemic symptoms (eg, generalized hives, respiratory or gastrointestinal problems, hypotension, angioedema, anaphylaxis) to rAvPAL-PEG or a PEG-containing product.
  • Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
  • Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study.
  • Known to rAvPAL-PEG or its , including hypersensitivity reactions that necessitated early termination from previous rAvPAL-PEG studies.
  • (ALT) concentration > 2 times the .
  • Creatinine > 1.5 times the upper limit of normal.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    rAvPAL-PEG

    rAvPAL-PEG in varying doses dependent on safety and efficacy.

    Drug: rAvPAL-PEG

Interventions

  • The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.

    Also known as: Pegvaliase

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Blood Phenylalanine (Phe) Concentration

    Blood Phe Concentration (Change from Baseline) and Daily Dose in PAL-003 Subjects by Disposition (PAL-003 Population)

    Time frame: At Baseline and Change from Baseline to Week 48, Week 96, Week 144, Week 216, and Week 240

Secondary outcomes

  1. Pharmacokinetics-Plasma Pegvaliase Concentration

    Steady-state Pharmacokinetics (PK) of pegvaliase was measured in subjects who have achieved and maintained target blood Phe

    Time frame: At Baseline, Week 48, Week 96, Week 144, Week 216 and Week 240

  2. Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

    A treatment-emergent AE was defined as any adverse event (AE) newly appearing or worsened in severity following initiation of study drug until 4 weeks after last dose of pegvaliase (PAL-003)

    Time frame: Up to 109 months.

  3. Percentage of Participants With Positive PEG IgG Antibody

    The presence of IgG Antibodies against PEG (polyethylene glycol) is measured overtime

    Time frame: At Baseline and Change from Baseline to Week 24, Week 52, Week 104 and Week 156

  4. Percentage of Participants With Positive PAL IgG Antibody

    The presence of IgG Antibodies against PAL (phenylalanine ammonia lyase) is measured overtime

    Time frame: At Baseline and Change from Baseline to Week 24, Week 52, Week 104 and Week 156

07

Results

Posted Oct 12, 2021

Participant flow

This was a multicenter study, conducted in 14 study centers of United States.

Participant flow — Overall Study
MilestonerAvPAL-PEG
Started68
Completed46
Not completed22
Withdrew: Withdrawal by subject11
Withdrew: Physician decision5
Withdrew: Lost to follow-up3
Withdrew: Adverse event2
Withdrew: Withdrawal by sponsor1

Outcome measures

PrimaryChange From Baseline in the Blood Phenylalanine (Phe) Concentration

Blood Phe Concentration (Change from Baseline) and Daily Dose in PAL-003 Subjects by Disposition (PAL-003 Population)

Time frame:
At Baseline and Change from Baseline to Week 48, Week 96, Week 144, Week 216, and Week 240
Reported as:
Mean · μmol/L
Change From Baseline in the Blood Phenylalanine (Phe) Concentration
μmol/LrAvPAL-PEG
Baseline1022.4 ± 530.39
Change from Baseline to Week 48-553.5 ± 652.95
Change from Baseline to Week 96-653.3 ± 637.81
Change from Baseline to Week 144-672.3 ± 621.06
Change from Baseline to Week 216-535.9 ± 573.08
Change from Baseline to Week 240-574.9 ± 549.90
SecondaryPharmacokinetics-Plasma Pegvaliase Concentration

Steady-state Pharmacokinetics (PK) of pegvaliase was measured in subjects who have achieved and maintained target blood Phe

Time frame:
At Baseline, Week 48, Week 96, Week 144, Week 216 and Week 240
Reported as:
Mean · ng/mL
Pharmacokinetics-Plasma Pegvaliase Concentration
ng/mLrAvPAL-PEG
At Baseline961.5 ± 3013.43
Week 484127.3 ± 6116.72
Week 967457.7 ± 10685.02
Week 1447196.1 ± 11678.89
Week 2167764.4 ± 9292.34
Week 2406557.8 ± 9220.95
SecondaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs)

A treatment-emergent AE was defined as any adverse event (AE) newly appearing or worsened in severity following initiation of study drug until 4 weeks after last dose of pegvaliase (PAL-003)

Time frame:
Up to 109 months.
Reported as:
Count of participants · Participants
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
ParticipantsrAvPAL-PEG
Subjects with any adverse event68
Subjects with any serious adverse events12
Subjects with any treatment-related adverse event65
Any treatment-related serious adverse event6
Death0
SecondaryPercentage of Participants With Positive PEG IgG Antibody

The presence of IgG Antibodies against PEG (polyethylene glycol) is measured overtime

Time frame:
At Baseline and Change from Baseline to Week 24, Week 52, Week 104 and Week 156
Reported as:
Count of participants · Participants
Percentage of Participants With Positive PEG IgG Antibody
ParticipantsrAvPAL-PEG
Baseline29
Change from Baseline to Week 2424
Change from Baseline to Week 5214
Change from Baseline to Week 1042
Change from Baseline to Week 1567
SecondaryPercentage of Participants With Positive PAL IgG Antibody

The presence of IgG Antibodies against PAL (phenylalanine ammonia lyase) is measured overtime

Time frame:
At Baseline and Change from Baseline to Week 24, Week 52, Week 104 and Week 156
Reported as:
Count of participants · Participants
Percentage of Participants With Positive PAL IgG Antibody
ParticipantsrAvPAL-PEG
Baseline10
Change from Baseline to Week 2463
Change from Baseline to Week 5260
Change from Baseline to Week 10448
Change from Baseline to Week 15645

Adverse events

Collected over Up to 109 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rAvPAL-PEG0/68 (0%)12/68 (17.6%)68/68 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventrAvPAL-PEG
AsthmaRespiratory, thoracic and mediastinal disorders2/68
HypersensitivityImmune system disorders1/68
Abortion inducedSurgical and medical procedures1/68
Anaphylactic reactionImmune system disorders1/68
AppendicitisInfections and infestations1/68
ArthralgiaMusculoskeletal and connective tissue disorders1/68
BacteraemiaInfections and infestations1/68
Bacterial infectionInfections and infestations1/68
Bone marrow failureBlood and lymphatic system disorders1/68
Diarrhoea infectiousInfections and infestations1/68
Most frequent other events
Showing 10 of 132
Most frequent other events
EventrAvPAL-PEG
NasopharyngitisInfections and infestations45/68
HeadacheNervous system disorders43/68
RashSkin and subcutaneous tissue disorders38/68
ArthralgiaMusculoskeletal and connective tissue disorders37/68
Injection site reactionGeneral disorders36/68
Injection site erythemaGeneral disorders36/68
Injection site bruisingGeneral disorders34/68
Upper respiratory tract infectionInfections and infestations34/68
UrticariaSkin and subcutaneous tissue disorders33/68
CoughRespiratory, thoracic and mediastinal disorders33/68

Baseline characteristics

All Enrolled Subjects

Age, Continuous
Age, Continuous(years)rAvPAL-PEG
Mean28.31 ± 8.66
Sex: Female, Male
Sex: Female, Male(Participants)rAvPAL-PEG
Female40
Male28
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)rAvPAL-PEG
Hispanic or Latino1
Not Hispanic or Latino67
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)rAvPAL-PEG
American Indian or Alaska Native1
White66
Asian1
Weight
Weight(kg)rAvPAL-PEG
Mean83.0 ± 26.39
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)rAvPAL-PEG
Mean29.2 ± 8.44
Baseline blood Phe
Baseline blood Phe(μmol/L)rAvPAL-PEG
Mean1022.4 ± 530.39
08

Study locations

14 sites
  • The Children's Hospital
    Aurora, Colorado 80045, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Ann and Robert H Lurie Children's Hospital
    Chicago, Illinois 60611, United States
  • University of Louisville, Kosair Charities Pediatric Clinical Research Unit
    Louisville, Kentucky 40202, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Washington University Center for Applied Research Sciences
    Saint Louis, Missouri 63110, United States
  • Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84108, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Burton BK, Longo N, Vockley J, Grange DK, Harding CO, Decker C, Li M, Lau K, Rosen O, Larimore K, Thomas J; PAL-002 and PAL-004 Investigators. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. Mol Genet Metab. 2020 Aug;130(4):239-246. doi: 10.1016/j.ymgme.2020.06.006. Epub 2020 Jun 16. PubMed 32593547 ↗
  • Longo N, Zori R, Wasserstein MP, Vockley J, Burton BK, Decker C, Li M, Lau K, Jiang J, Larimore K, Thomas JA. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study. Orphanet J Rare Dis. 2018 Jul 4;13(1):108. doi: 10.1186/s13023-018-0858-7. PubMed 29973227 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2010 to primary completion in Jan 2019, 108 months.

Results were first posted in Oct 2021, 2 years 8 months after primary completion. A results delay was requested in Dec 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2009
First posted
Jun 19, 2009
StartActual
Jan 13, 2010
Primary completionActual
Jan 31, 2019
CompletionActual
Jan 31, 2019
Results delay requested
Dec 6, 2019
Results first posted
Oct 12, 2021
Last update
Oct 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00924703
Responsible party
Sponsor
First posted
Jun 19, 2009
Start date
Jan 13, 2010
Primary completion
Jan 31, 2019
Completion
Jan 31, 2019
Results posted
Oct 12, 2021
Last update
Oct 12, 2021

Study contacts

Medical Director, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegvaliase

Start the discussion